Yang Qingrui, Yu Chengcheng, Yang Zhaowen, Wei Qing, Mu Kun, Zhang Ying, Zhao Wei, Wang Xiaofeng, Huai Wanwan, Han Lihui
From the Department of Immunology, Shandong University School of Medicine; the Provincial Hospital Affiliated to Shandong University; and the Department of Pathology, Shandong University School of Medicine, Jinan, China.
J Rheumatol. 2014 Mar;41(3):444-52. doi: 10.3899/jrheum.130310. Epub 2013 Dec 15.
NOD-like receptor family, pyrin domain containing 3 and 1 (NLRP3 and NLRP1) inflammasomes are molecular platforms that sense the damage or danger signals of cells. We investigated whether NLRP3/NLRP1 inflammasomes are involved in the pathogenesis and progression of systemic lupus erythematosus (SLE).
Expressions of inflammasome components at the mRNA and protein levels in the peripheral blood mononuclear cells (PBMC) from patients with SLE and healthy controls were investigated by quantitative real-time transcription PCR and Western blot, respectively. Correlations between NLRP3/NLRP1 inflammasome components' expression and clinical disease progression were investigated. Expressions of NLRP3/NLRP1 inflammasomes before and after treatment in the patients with SLE were also analyzed and compared.
Our data showed that expressions of NLRP3/NLRP1 inflammasomes were significantly downregulated in PBMC from patients with SLE compared with PBMC from healthy controls. Further, expressions of NLRP3/NLRP1 inflammasomes were negatively correlated with the SLE Disease Activity Index, and regular glucocorticoid treatment significantly corrected this deregulation of these inflammasomes. Further analysis showed that type I interferon (IFN) level was significantly negatively correlated with expression of NLRP3/NLRP1 inflammasomes, which indicated that enhanced IFN-I level in patients with SLE was responsible, at least to a great degree, for the deregulation of inflammasomes.
These results indicated deregulation of NLRP3/NLRP1 inflammasomes in patients with SLE, and suggested an important role for inflammasomes in the pathogenesis and progression of SLE.
含吡啉结构域的NOD样受体家族3和1(NLRP3和NLRP1)炎性小体是感知细胞损伤或危险信号的分子平台。我们研究了NLRP3/NLRP1炎性小体是否参与系统性红斑狼疮(SLE)的发病机制和病情进展。
分别采用定量实时转录PCR和蛋白质印迹法,研究SLE患者和健康对照外周血单个核细胞(PBMC)中炎性小体成分在mRNA和蛋白质水平的表达。研究NLRP3/NLRP1炎性小体成分表达与临床疾病进展之间的相关性。还分析比较了SLE患者治疗前后NLRP3/NLRP1炎性小体的表达。
我们的数据显示,与健康对照的PBMC相比,SLE患者PBMC中NLRP3/NLRP1炎性小体的表达显著下调。此外,NLRP3/NLRP1炎性小体的表达与SLE疾病活动指数呈负相关,常规糖皮质激素治疗显著纠正了这些炎性小体的这种失调。进一步分析表明,I型干扰素(IFN)水平与NLRP3/NLRP1炎性小体的表达显著负相关,这表明SLE患者中升高的IFN-I水平至少在很大程度上导致了炎性小体的失调。
这些结果表明SLE患者中NLRP3/NLRP1炎性小体失调,并提示炎性小体在SLE的发病机制和病情进展中起重要作用。